NovoCureBSP:N2VC34 46 PS Ratio is 0.22 as of Jun. 25, 2026, which is 98% below its 10-year median of 13.02. GuruFocus rates BSP:N2VC34 with a GF Score™ of 46/100 and a GF Value™ of R$8.98 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 804 Medical Devices & Instruments companies, NovoCure ranks better than 54.85% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, NovoCure's share price is R$7.08.
NovoCure's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was R$32.37. Hence, NovoCure's PS Ratio for today is 0.22.
The historical rank and industry rank for NovoCure's PS Ratio or its related term are showing as below:
BSP:N2VC34'
s PS Ratio Range Over the Past 10 Years
Min: 1.73 Med: 13.02 Max: 45.11
Current: 2.45
During the past 13 years, NovoCure's highest PS Ratio was 45.11. The lowest was 1.73. And the median was 13.02.
BSP:N2VC34's PS Ratio is ranked better than 54.85% of 804
companies
in the Medical Devices & Instruments industry
Industry Median: 2.865
vs BSP:N2VC34: 2.45
NovoCure's Revenue per Sharefor the
three
months ended in Mar. 2026 was R$7.97.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was R$32.37.
During the past 12 months, the average Revenue per Share Growth Rate of NovoCure was 4.80% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 4.60% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 4.30% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 19.60% per year.
During the past 13 years, NovoCure's highest 3-Year average Revenue per Share Growth Rate was 110.30% per year. The lowest was 1.80% per year. And the median was 27.85% per year.
Back to Basics: PS Ratio
NovoCure (BSP:N2VC34) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
NovoCure PS Ratio Related Terms
NovoCure PS Ratio Historical Data
* Premium members only.
The historical data trend for NovoCure's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:N2VC34 vs NEOG, ESTA, AXGN: PS Ratio Comparison
For the Medical Devices subindustry, NovoCure's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NovoCure PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NovoCure's PS Ratio distribution charts can be found below:
* The bar in red indicates where NovoCure's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
NovoCure's Share Price of today is R$7.08. NovoCure's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$32.37.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
NovoCure (BSP:N2VC34) has a PS Ratio of 0.22 as of Jun. 25, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on NovoCure and its competitors. This is 98% below median its historical median of 13.02. Over the past decade, NovoCure's PS Ratio has ranged from 1.73 to 45.11. According to the industry distribution chart, NovoCure ranks #363 out of 804 companies in the Medical Devices & Instruments industry, placing it in the top 45.1%.
Is NovoCure's PS Ratio too high?
NovoCure's current PS Ratio of 0.22 is 98% below median its 10-year median of 13.02. Over the past 10 years, this metric has ranged from a low of 1.73 to a high of 45.11. The Medical Devices & Instruments industry median PS Ratio is 2.87. NovoCure's value of 0.22 is 92.3% below this industry median. Based on the distribution chart, NovoCure ranks #363 out of 804 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, NovoCure has a GF Score™ of 46/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NovoCure's PS Ratio compare to NEOG and ESTA?
According to the Medical Devices & Instruments industry distribution chart, NovoCure ranks #363 out of 804 companies for PS Ratio. This puts NovoCure in the upper half of its industry. The industry median PS Ratio is 2.87. NovoCure's value of 0.22 is 92.3% below this benchmark. Historically, NovoCure's own PS Ratio has ranged from 1.73 to 45.11 over the past decade. While the company's 10-year median is 13.02 vs. the industry median of 2.87, NovoCure has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.87, based on 804 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NovoCure's current PS Ratio of 0.22 is 92.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on NovoCure and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NovoCure's current PS Ratio is 0.22, which is 98% below median its own 10-year median of 13.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NovoCure stock overvalued right now?
Based on GuruFocus' analysis, NovoCure (BSP:N2VC34) is currently considered Modestly Undervalued. The stock's GF Value™ is R$8.98, compared to a current price of R$7.08 — trading 21.2% below its estimated fair value. The current PS Ratio is 0.22, which is 98% below median its 10-year median of 13.02 and 92.3% below the Medical Devices & Instruments industry median of 2.87. NovoCure's overall GF Score™ is 46/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For NovoCure (BSP:N2VC34), the current PS Ratio is 0.22 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NovoCure (BSP:N2VC34) Overvalued in 2026?
Based on GuruFocus' analysis, NovoCure stock appears to be undervalued.
The current stock price of R$7.08 is trading 21.2% below its estimated GF Value™ of R$8.98.
GuruFocus considers NovoCure to be Modestly Undervalued.
Key valuation signals for BSP:N2VC34:
PS Ratio: 0.22 (98% below median its 10-year median of 13.02)
GF Value™: R$8.98 vs. price of R$7.08 (21.2% below fair value)
Industry Position: 92.3% below the Medical Devices & Instruments median (#363 of 804)
No single metric tells the full story. See the BSP:N2VC34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
46GF Score
Get the complete analysis for BSP:N2VC34
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:N2VC34 has been successfully added to your 
